CLAL BIOTECHNOLOGY INDUSTRIES LTD. Financials Clal Biotechnology Industries Ltd.
Equities
CBI
IL0011042806
Investment Holding Companies
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.9 ILa | -2.73% |
|
-0.60% | +25.69% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 434.5 | 210.9 | 318.5 | 185.4 | 98.5 | 62.27 |
| Enterprise Value (EV) 1 | 380.4 | 159 | 182.8 | 186.1 | 122.3 | 84.67 |
| P/E ratio | -9.51 x | -1.37 x | 2.92 x | -2.07 x | -1.6 x | -2.01 x |
| Yield | - | - | 11.1% | - | - | - |
| Capitalization / Revenue | 34 x | 1.86 x | 4.26 x | 2.41 x | 266 x | 599 x |
| EV / Revenue | 29.8 x | 1.4 x | 2.44 x | 2.42 x | 331 x | 814 x |
| EV / EBITDA | -5.39 x | 26.3 x | -4.97 x | -4.21 x | 26.6 x | -8.44 x |
| EV / FCF | -4.73 x | 5.91 x | -7.9 x | -13.3 x | 19.5 x | -15.6 x |
| FCF Yield | -21.1% | 16.9% | -12.7% | -7.54% | 5.12% | -6.42% |
| Price to Book | 1.09 x | 0.94 x | 1.04 x | 1.07 x | 0.78 x | 0.63 x |
| Nbr of stocks (in thousands) | 161,236 | 161,236 | 161,104 | 156,846 | 156,846 | 156,846 |
| Reference price 2 | 2.695 | 1.308 | 1.977 | 1.182 | 0.6280 | 0.3970 |
| Announcement Date | 3/27/19 | 3/23/20 | 3/18/21 | 3/29/22 | 3/30/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 12.77 | 113.3 | 74.82 | 76.96 | 0.37 | 0.104 |
| EBITDA 1 | -70.58 | 6.039 | -36.82 | -44.24 | 4.598 | -10.03 |
| EBIT 1 | -85.42 | -12.44 | -60.68 | -66.75 | -12.51 | -10.18 |
| Operating Margin | -669.07% | -10.98% | -81.11% | -86.73% | -3,380% | -9,789.42% |
| Earnings before Tax (EBT) 1 | -40.87 | -357.9 | 49.84 | -128.1 | -41.02 | -28.09 |
| Net income 1 | -44.94 | -154.1 | 109 | -89.58 | -61.74 | -31.05 |
| Net margin | -352.02% | -136.03% | 145.73% | -116.4% | -16,686.49% | -29,856.73% |
| EPS 2 | -0.2835 | -0.9558 | 0.6762 | -0.5700 | -0.3936 | -0.1980 |
| Free Cash Flow 1 | -80.39 | 26.93 | -23.14 | -14.03 | 6.264 | -5.439 |
| FCF margin | -629.69% | 23.77% | -30.94% | -18.23% | 1,692.87% | -5,229.93% |
| FCF Conversion (EBITDA) | - | 445.86% | - | - | 136.22% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | 0.2200 | - | - | - |
| Announcement Date | 3/27/19 | 3/23/20 | 3/18/21 | 3/29/22 | 3/30/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 0.73 | 23.8 | 22.4 |
| Net Cash position 1 | 54.1 | 51.9 | 136 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.0166 x | 5.186 x | -2.233 x |
| Free Cash Flow 1 | -80.4 | 26.9 | -23.1 | -14 | 6.26 | -5.44 |
| ROE (net income / shareholders' equity) | -3.45% | -47.8% | 9.85% | -30.1% | -17% | -21.1% |
| ROA (Net income/ Total Assets) | -5.21% | -0.95% | -6.16% | -7.88% | -2.49% | -3.73% |
| Assets 1 | 863 | 16,188 | -1,769 | 1,137 | 2,479 | 832.2 |
| Book Value Per Share 2 | 2.470 | 1.390 | 1.900 | 1.100 | 0.8000 | 0.6300 |
| Cash Flow per Share 2 | 0.2500 | 0.2300 | 0.4200 | 0.3400 | 0.0500 | 0.0400 |
| Capex 1 | 2.91 | 2.83 | 3.19 | 1.59 | 1.27 | 0.01 |
| Capex / Sales | 22.76% | 2.5% | 4.26% | 2.07% | 344.05% | 4.81% |
| Announcement Date | 3/27/19 | 3/23/20 | 3/18/21 | 3/29/22 | 3/30/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +25.69% | 21.17M | |
| +19.18% | 79.51B | |
| +72.64% | 18.81B | |
| +12.09% | 17.62B | |
| +10.55% | 14.64B | |
| +4.34% | 13.24B | |
| +5.80% | 11.88B | |
| +7.01% | 11.11B | |
| +37.56% | 10.61B | |
| +0.46% | 10.02B |
- Stock Market
- Equities
- CBI Stock
- Financials Clal Biotechnology Industries Ltd.